Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers

SIMPLE SUMMARY: The development of BCL-2 inhibitors as a pivotal approach in cancer treatment lies in their ability to effectively trigger apoptosis in tumor cells. Venetoclax, a highly selective BCL-2 inhibitor, has exhibited robust antitumor capacity in hematologic malignancies. However, patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jiaxuan, Dong, Xiaoqing, Huang, David C. S., Xu, Peipei, Zhao, Quan, Chen, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605442/
https://www.ncbi.nlm.nih.gov/pubmed/37894324
http://dx.doi.org/10.3390/cancers15204957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605442/
https://www.ncbi.nlm.nih.gov/pubmed/37894324
http://dx.doi.org/10.3390/cancers15204957

Ejemplares similares